Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Pricing Clinical Trials Drug Safety Weight Loss Weight Loss Drugs Cancer Treatment Drug Regulation Medications

FDA Clears Wegovy Weight-Loss Pill, First Oral GLP-1 for Obesity, With January U.S. Launch

The first oral option in this class could broaden uptake by removing injections as a barrier.

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

Large Swedish Study Finds ARBs Sustain the Best Long-Term Adherence in Hypertension

FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

BioMarin to Acquire Amicus for $4.8 Billion in Cash

White House Secures Nine More Drugmaker Pacts on MFN Pricing as TrumpRx Nears Launch

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance